LABS, Inc. Names Sarah Dennison as Vice President of Commercial Operations

CENTENNIAL, Colo.--(BUSINESS WIRE)--LABS, Inc., a Centennial-based comprehensive, highly accredited specialized clinical reference testing laboratory, announced it has appointed Sarah Dennison, MBA, as Vice President of Commercial Operations. Based at LABS, Inc. Centennial headquarters, Dennison is responsible for leading the teams that provide strategic sales and marketing growth strategies. Her teams are known for both innovation and execution, and include commercial insight, customer and sales services, and marketing services.

"As we continue to expand our operation, it's imperative that we have in-depth commercial strength across all areas of the organization. Her experience and leadership qualities lend themselves well to our team realizing our ambitions"
Dennison has nearly two decades of multi-functional experience in the pharma, diagnostics and laboratory services industry, bringing commercial leadership and expertise to LABS, Inc. Prior to joining the company, she served in various scientific and commercial roles at GeneDx, Pathway Genomics, Quidel Corp., and Sequenom.

"As we continue to expand our operation, it's imperative that we have in-depth commercial strength across all areas of the organization. Her experience and leadership qualities lend themselves well to our team realizing our ambitions," said Todd Johnson, President and CEO. "Dennison has a clear passion for the life sciences industry and we are very excited to have her on the team and look forward to her contributions to our success."

Dennison has a Bachelor of Science degree in Chemistry from Covenant College. She also holds a Master of Business Administration from Point Loma Nazarene University.

About LABS, Inc.

Founded in 1978 as Immunological Associates of Denver, now known as LABS, Inc., LABS operates laboratories in Centennial, Colorado and Philadelphia, Pennsylvania. Each facility is independently certified, accredited, licensed or registered by numerous agencies that may include AABB, American Society of Histocompatibility and Immunogenetics (ASHI), the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), the U.S. Food and Drug Administration (FDA), International Organization of Standardization (ISO) and the states of California, Florida, Maryland, New York, Pennsylvania, Rhode Island and West Virginia. For more information about LABS, Inc., visit www.labs-inc.org.

Contacts

LABS, Inc.
Jessica O'Neale, 720-528-4722
[email protected]
www.labs-inc.org

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.

The platform is intended to enable Bayer to make its expertise and resources available to its partners while preserving their autonomy and culture.